Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

The goal of our study is to explore how treatments affect the bone immune microenvironment and determine the best treatment options for patients with metastatic kidney cancer to the bone. This could prevent skeletal complications and improve patient outcomes.

Trial Details

NCT ID
NCT07187869
Phase
PHASE1
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Cabozantinib
  • Nivolumab
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • To be eligible for the study, the subject must meet all of the inclusion and none of the exclusion criteria.
  • Signed Written Informed Consent
  • Ability to understand and the willingness to sign a written informed consent document.
  • Participants must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guideline…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →